C
24.46
0.77 (3.25%)
| Penutupan Terdahulu | 23.69 |
| Buka | 23.59 |
| Jumlah Dagangan | 318,924 |
| Purata Dagangan (3B) | 384,153 |
| Modal Pasaran | 741,039,232 |
| Harga / Jualan (P/S) | 2.06 |
| Harga / Buku (P/B) | 1.57 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 May 2026 |
| Margin Keuntungan | -1.46% |
| Margin Operasi (TTM) | -31.74% |
| EPS Cair (TTM) | -0.190 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 20.60% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.87% |
| Nisbah Semasa (MRQ) | 9.37 |
| Aliran Tunai Operasi (OCF TTM) | 65.67 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 44.64 M |
| Pulangan Atas Aset (ROA TTM) | -1.80% |
| Pulangan Atas Ekuiti (ROE TTM) | -1.20% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Castle Biosciences, Inc. | Menurun | Menaik |
AISkor Stockmoo
-0.4
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | -1.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.40 |
|
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.98% |
| % Dimiliki oleh Institusi | 93.02% |
| Julat 52 Minggu | ||
| Median | 44.00 (79.89%) | |
| Jumlah | 1 Beli | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Baird | 27 Feb 2026 | 44.00 (79.89%) | Beli | 29.57 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| MAETZOLD DEREK J | - | 24.58 | -4,172 | -102,548 |
| Jumlah Keseluruhan Kuantiti Bersih | -4,172 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -102,548 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 24.58 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | Pegawai | 21 Apr 2026 | Jual automatik (-) | 550 | 24.58 | 13,519 |
| MAETZOLD DEREK J | Pegawai | 21 Apr 2026 | Jual automatik (-) | 3,622 | 24.58 | 89,029 |
| MAETZOLD DEREK J | Pegawai | 21 Apr 2026 | Pelaksanaan pilihan | 550 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 05 Feb 2026 | Pengumuman | Castle Biosciences to Release Fourth Quarter and Full-Year 2025 Financial Results and Host Conference Call on Thursday, Feb. 26, 2026 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |